FIGHT METASTASES WITH THE BODY’S OWN WEAPONS
VCC-001 can prevent the development of metastases and significantly prolong patients’ lives as a result. The effect of VCC-001 has been clearly proven in studies. Since it is prepared from the patients’ tissue, it is almost free of side effects.
VCC-001 is used in non-metastatic renal cell carcinomas. It is prepared from the patient’s tumour and stimulates the immune system to fight the remaining tumour cells and thereby reduce the risk of recurrence and the development of metastases.
A study published in “The Lancet” in February 2004 showed that patients who were treated with VCC-001 have a significantly higher life expectancy. Specifically, this means that patients who were treated with VCC-001 lived for 31 months longer on average. Mortality without VCC-001 is 1.33 times higher than with VCC-001 (and even 1.6 times higher in those under the age of 61).